Regeneron raises 2026 guidance, lifting adjusted product gross margin to ~86%, after beat

 

Regeneron raises 2026 guidance, lifting adjusted product gross margin to ~86%, after beating Q3 2026 estimates with EPS $20.07 and $5.1B revenue

• 2026 guidance update includes revised R&D and SG&A expense forecasts, in addition to higher adjusted gross margin on product sales.
• Strong Q3 2026 performance driven by Dupixent, EYLEA HD and Libtayo across key therapeutic areas.

https://finviz.com/stock?t=REGN&ty=c&ta=1&p=d